Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 14/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.51 |
| ▸ | GIPR | P48546 | 6/20 | 0.50 |
| ▸ | GCG | P01275 | 1/20 | 0.50 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.44 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13800413 | 0.91 | GCGR (0.53) | GCGRGIPRGCGSTAT3 | |
| SCHEMBL4085339 | 0.90 | GCGR (0.58) | GCGRGIPRGCG | |
| SCHEMBL4082013 | 0.88 | GCGR (0.62) | GCGRGIPRSTAT3 | |
| SCHEMBL13799984 | 0.88 | GCGR (0.54) | GCGRGIPRGCGSTAT3 | |
| SCHEMBL2663172 | 0.88 | GCGR (0.56) | GCGRGIPRGCGSTAT3 | |
| SCHEMBL4091259 | 0.86 | GCGR (0.58) | GCGRGIPRGCG | |
| SCHEMBL4092421 | 0.86 | GCGR (0.55) | GCGRGIPRGCGSTAT3 | |
| SCHEMBL9070989 | 0.85 | GCGR (0.54) | GCGRGIPRGCG | |
| SCHEMBL13800864 | 0.85 | GCGR (0.53) | GCGRGIPRGCG | |
| SCHEMBL2663543 | 0.85 | GCGR (0.53) | GCGRGIPRGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| EP-1183229-B1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK AS (DK) | 2005-10-26 | — | — | EP | disclosed |
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2005-09-15 | — | — | US | disclosed |
| US-6875760-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2005-04-05 | — | — | US | disclosed |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2003-11-27 | — | — | US | disclosed |
| US-6503949-B1 | Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity | NORO NORDISK A/S (DK) | 2003-01-07 | — | — | US | disclosed |
| CN-1356977-A | Glucagon antagonists/inverse agonists | NOVO NORDISK AS (DK) | 2002-07-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | GCGR 3/4885HDAC11 2304/4885HDAC8 2820/4885 |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | GLP1R, GPR119, GCGR | GCGR 3/4885HDAC11 2304/4885HDAC8 2820/4885 |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | GCGR 3/4885HDAC11 2304/4885HDAC8 2820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.